Unicycive Therapeutics UNCY Income Statement (2020-2026)

NASDAQ UNCY
$5.45 -0.13 (-2.33%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
1.50M1.17M1.50M1.50M1.51M1.52M1.52M1.52M3.48M2.45M3.76M4.36M9.79M6.70M11.97M14.11M20.85M15.89M25.24M27.86M
Revenue & cost
Revenue (Quarter)
0.95M0.68M
Operating items
Research & Development (Quarter)
0.17M-1.48M1.93M1.86M0.10M12.13M3.03M2.27M3.37M4.23M6.81M4.87M3.04M5.29M2.17M1.75M2.96M2.25M1.61M2.79M
Selling, General & Administrative (Quarter)
0.07M1.39M0.19M1.78M0.16M1.49M1.85M2.06M2.57M2.08M2.39M2.53M3.21M3.97M5.82M5.21M4.38M4.97M6.83M7.35M
Other Operating Expenses (Quarter)
4.48M2.84M1.41M-0.00M-8.29M-10.37M0.48M1.60M
Operating Expenses (Quarter)
4.71M2.75M3.54M3.64M6.50M5.33M4.88M4.32M5.94M6.31M9.20M7.40M6.25M9.26M7.99M6.96M7.34M7.22M8.44M10.14M
Operating Income (Quarter)
-4.71M-2.75M-3.54M-3.64M-5.55M-5.33M-4.20M-4.32M-5.94M-6.31M-9.20M-7.40M-6.25M-9.26M-7.99M-6.96M-7.34M-7.22M-8.44M-10.14M
EBIT (Quarter)
-4.71M-2.75M-3.54M-3.64M-5.55M-5.33M-4.20M-4.32M-5.94M-6.31M-9.20M-7.40M-6.25M-9.26M-7.99M-6.96M-7.34M-7.22M-8.44M-10.14M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.23M0.23M0.14M0.07M0.46M0.42M0.31M0.23M0.15M0.28M0.35M0.39M0.44M
Other Non Operating Income (Quarter)
-10.37M-11.76M
Non Operating Income (Quarter)
-0.49M-0.00M-0.00M-10.38M0.48M1.60M-1.49M-11.76M17.26M2.15M-12.26M8.56M0.52M1.33M-7.44M-4.39M8.42M
Net income details
EBT (Quarter)
-4.77M-2.56M-3.81M-3.87M-5.75M-5.33M-233.26M-106.94M-40.97M-6.19M-9.23M-7.63M-6.71M-8.91M-7.86M-12.22M-14.57M-6.44M-19.91M-17.60M
Profit After Tax (Quarter)
-5.20M-2.75M-3.54M-3.64M-5.56M-5.33M-14.57M-3.84M-4.33M-6.93M-20.96M9.86M-4.10M-22.62M0.57M-6.45M-6.01M-14.67M-12.82M-1.75M
Income from Non-Controlling Interests (Quarter)
6.00M17.00M
Income from Continuing Operations (Quarter)
-4.77M-2.56M-3.81M-3.87M-5.75M-5.33M-233.26M-106.94M-40.97M-6.19M-9.23M-7.63M-6.71M-8.91M-7.86M-12.22M-14.57M-6.44M-19.91M-17.60M
Consolidated Net Income (Quarter)
-4.77M-2.56M-3.81M-3.87M-5.75M-5.33M-233.26M-106.94M-40.97M-6.19M-9.23M-7.63M-6.71M-8.91M-7.86M-12.22M-14.57M-6.44M-19.91M-17.60M
Income towards Parent Company (Quarter)
-4.77M-2.56M-3.81M-3.87M-5.75M-5.33M-233.26M-106.94M-40.97M-6.19M-9.23M-7.63M-6.71M-8.91M-7.86M-12.22M-14.57M-6.44M-19.91M-17.60M
Preferred Dividend Payments (Quarter)
0.19M0.60M0.07M0.21M0.89M
Net Income towards Common Stockholders (Quarter)
-5.20M-2.75M-3.54M-3.64M-5.56M-5.33M-14.77M-4.44M-4.41M-7.80M-21.17M3.04M-4.10M-21.52M0.51M-6.45M-6.01M-6.44M-12.82M-1.72M
Additional items
EPS (Basic) (Quarter)
-3.67-2.36-2.36-2.42-3.69-3.54-9.69-2.92-1.35-3.18-6.060.80-0.46-3.210.04-0.52-0.33-0.41-0.54-0.07
EPS (Diluted) (Quarter)
-3.67-2.36-2.36-2.42-3.69-3.54-9.69-2.92-1.35-3.18-6.060.32-0.46-3.210.04-0.52-0.33-0.41-0.54-0.07
Shares Outstanding (Quarter)
1.42M1.17M1.50M1.50M1.51M1.51M1.52M1.52M3.26M2.45M3.49M3.79M8.89M6.70M11.68M12.30M18.07M15.89M23.91M23.91M
Shares Outstanding (Diluted) (Quarter)
1.42M1.17M1.50M1.50M1.51M1.51M1.52M1.52M3.26M2.45M3.49M9.41M8.89M6.70M12.38M12.30M18.07M15.89M23.91M23.91M
EBITDA (Quarter)
-4.71M-2.75M-3.54M-3.64M-5.55M-5.33M-4.20M-4.32M-5.94M-6.31M-9.20M-7.40M-6.25M-9.26M-7.99M-6.96M-7.34M-7.22M-8.44M-10.14M
Interest Expenses (Quarter)
0.06M-0.19M0.27M0.23M0.19M0.00M229.07M102.86M35.25M0.02M0.10M0.69M0.87M-0.04M0.10M5.41M7.51M-0.43M11.86M7.90M